Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
This presentation will delve into the complexities of sustaining the global HIV commitment amidst evolving health priorities and funding landscapes. This session will explore the opportunities and risks of integrating HIV care and prevention into broader health services. From innovative service delivery models to community-driven solutions, we will highlight how integration can enhance health system…
Current ART has the capacity to drastically suppress but not abolish previously infected cells which can persist for the life of the host. This persistent rebound competent virus is the primary barrier to HIV cure. This long-term stable virus resides in multiple subsets of CD4+ T cells, particularly CD4+ memory T cells, and possibly macrophages…
Recent research underscored that HIV transcription remains a critical step in the viral life cycle. Especially the transition between active and latent infection is critically regulated by viral factors such as Tat and many host factors that either control the transcriptional activity of the virus directly or the epigenetic landscape around it. It has become…
HIV persists in the central nervous system (CNS), and a subset of PWH develop neurocognitive issues despite virally suppression. With a diverse set of infected cells comprising the CNS reservoir, along with the impact of both acute and chronic infection on local inflammation and blood brain barrier integrity, the CNS presents an important and unique…
This talk will highlight the burden and spectrum of post-tuberculosis disease, focusing on the complexities of clinical presentation and pitfalls in assessment. We will give an overview of pathogenesis, and an update of recent work in post-tuberculosis lung disease (PTLD). We will highlight important knowledge gaps in the field, and will discuss ongoing work and…
Long-acting injectables (LAI) represents one of the most significant advances in antiretroviral therapy in recent years, offering durable suppression for PLWH who find daily oral medications challenging. Confirmed virological failure (CVF) is a low-incidence (1.4% over 152 weeks) but high-consequence event, with almost all developing drug-resistant mutations. This is in contrast to daily oral INSTI-based…
Antiretroviral therapy (ART) has transformed HIV-1 infection from a fatal disease into a manageable chronic condition. However, longitudinal studies reveal that the decay rate of the HIV-1 reservoir is so slow that ART alone cannot eliminate the reservoir within the lifetime of people living with HIV-1 (PLWH). This underscores the urgent need for safe and…
Cellular and tissue sources of viral rebound primarily originate from long-lived reservoirs of HIV in individuals under antiretroviral therapy (ART). Key cellular reservoirs include CD4+ T cells, particularly memory subsets like central memory (Tcm), which harbor latent provirus. Tissue-specific sources include lymphoid tissues (lymph nodes, spleen, and gut-associated lymphoid tissue), where virus can persist despite…
Is testing the key to unlocking PrEP scale-up? The use of antiretroviral drugs (ARVs) to prevent new HIV infections has been well-established for decades, particularly in the context of pre-exposure prophylaxis (PrEP). Yet, only an estimated 2.5 million people are currently using PrEP—far fewer than the 10 million needed to meet global HIV prevention goals…
We are at the dawn of a new era of long-acting antiretroviral (ARV) agents that promises to revolutionize the prevention of HIV infection. The HPTN083 and 084 studies first demonstrated the promise of cabotegravir for HIV pre-exposure prophylaxis (PrEP), but its use needs to be balanced with frequent injections, risks of drug resistance and challenges…